Loading clinical trials...
Loading clinical trials...
A Non-interventional Study Evaluating Injectable Treatments (Ofatumumab, Glatiramer Acetate and Interferon β1) and Oral Treatments (Teriflunomide, Dimethyl Fumarate and Diroximel Fumarate) in Patients With Relapsing Multiple Sclerosis [AIOLOS]
Conditions
Interventions
ofatumumab
glatiramer acetate
+4 more
Locations
119
Germany
Novartis Investigative Site
Hettingen, Baden-Wurttemberg, Germany
Novartis Investigative Site
Mannheim, Baden-Wurttemberg, Germany
Novartis Investigative Site
Nagold, Baden-Wurttemberg, Germany
Novartis Investigative Site
Schwäbisch Hall, Baden-Wurttemberg, Germany
Novartis Investigative Site
Schwetzingen, Baden-Wurttemberg, Germany
Novartis Investigative Site
Bamberg, Bavaria, Germany
Start Date
May 10, 2022
Primary Completion Date
May 30, 2029
Completion Date
May 30, 2029
Last Updated
April 1, 2026
NCT07426991
NCT06433752
NCT06617793
NCT04047628
NCT06486779
NCT04121065
Novartis Pharmaceuticals
CONTACT
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions